What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)?

In different development, Bernstein reiterated its Hold standing connected Bristol-Myers Squibb Company (NYSE:BMY) connected February 10 and acceptable a terms people of $58.00. Bristol-Myers Squibb Company (NYSE:BMY) besides received a standing update from Morgan Stanley connected February 6, which lifted the terms people connected the banal to $40 from $37 portion keeping an Underweight standing connected the shares. The steadfast told investors successful a probe enactment that portion the 2026 gross and EPS guidance exceeded consensus, it was driven by a higher-than-expected Eliquis guide.

The standing updates came aft Bristol-Myers Squibb Company (NYSE:BMY) reported fiscal Q4 and full-year fiscal results for 2025, reporting a 1% maturation successful fiscal Q4 gross to $12.5 billion, with maturation portfolio gross rising 16% to $7.4 billion. Full-year revenues reached $48.2 billion, and maturation portfolio revenues accrued 17% to $26.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) is simply a biopharmaceutical institution that discovers, develops, and delivers precocious medicines for superior diseases. Its medicines autumn into assorted therapeutic classes, including oncology, cardiovascular, immunology, and neuroscience.

While we admit the imaginable of BMY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.